In vivo detection of Alzheimer's and Lewy body disease concurrence: Clinical implications and future perspectives.

ABSTRACT:

Introduction

The recent introduction of seed amplification assays (SAAs) detecting misfolded α-synuclein, a pathology-specific marker for Lewy body disease (LBD), has allowed the in vivo identification and phenotypic characterization of patients with co-occurring Alzheimer's disease (AD) and LBD since the early clinical or even preclinical stage.

Methods

We reviewed studies with an in vivo biomarker-based diagnosis of AD-LBD copathology.

Results

Studies in large cohorts of cognitively impaired individuals have shown that cerebrospinal fluid (CSF) biomarkers detect the coexistence of AD and LB pathology in approximately 20%-25% of them, independently of the primary clinical diagnosis. Compared to those with pure AD, AD-LBD patients showed worse global cognition, especi

SUBMITTER: Baiardi S 

PROVIDER: S-EPMC11350051 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature